Group of rare blood cancers respond to new treatment pioneered by Stanford physician

A global trial of an oral medication called midostaurin indicates that the drug can produce partial or complete resolution of organ damage in 60 percent of patients with a group of rare blood…



Source link

Would you like to get the test?